Credibility and trustworthiness in AI models are related but distinct attributes. If you're using them in GMP manufacturing, you should understand the difference.
- Why Improving Drug Delivery Remains A Major Opportunity In Oncology
- FDA's Guidance On Cell And Gene CMC Codifies Flexibility
- Strategic Synthesis Of ASGCT And ASCO 2026
- Emerging Technologies In Aseptic Processing: Hype Vs. Operational Reality
- Use Of AI In FDA Inspection Activities: Strategies For Effective Preparation
- A Comparison Of 6 Analytical Validation Guidelines Using Data Envelopment Analysis
- Inside AstraZeneca's Fully Electrified Cell Therapy Facility
- AI Has Arrived In Biotech CMC Amid Patchwork Governance
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Leveraging Integrated Media Services For Speed And Efficiency
Uncertainty in media stability can limit efficiency and scalability in biologics manufacturing. See how a data-driven approach enables more predictable planning and reduces operational strain.
-
Scale-Up Of AAV Production In Fixed-Bed Bioreactors
Consistent AAV production is critical for manufacturing. See how aligned strategies deliver comparable cell growth, metabolic trends, and rAAV5 titers from development through production.
-
The Role Of Extractables Data In The Adoption Of Single-Use Systems
Explore guidance for evaluating single-use systems for extractables and leachables, and learn how supplier-provided single-use system extractables data can save both time and resources.
-
Amino Acid Analysis Indicates Metabolic Differences In MCB CAR T-Cells
Exploring the metabolic differences in CAR T-cells activated with multi-cytokine backpacks (MCBs) reveals correlations between CAR T-cell activation, nutrient metabolism, and efficacy.
-
iPSC Aggregate Culture In Bioreactors Equipped With 8-Blade Impellers
Controlled aggregation, oxygen management, and scalable workflows drive consistent iPSC expansion. Parallelized systems and precise parameter control improve reproducibility for faster optimization and confident transitions.
-
How We Used Intelligent Automation to Transform Vendor Selection
Discover how your small biotech can achieve faster timelines, improved cost control, and more strategic, transparent choices with a platform leveraging intelligent automation.
-
ADC Development Grows More Complex — SPR Insights Bring Clarity
Explore how real-time kinetic analysis reveals how conjugation, linker chemistry, and drug loading influence antibody–antigen interactions, while enabling sensitive detection of anti-drug antibodies.
-
Small Volume ATMP Cryo-Freezing Strategies
Discover best practices for cryopreserving small-volume ATMPs, focusing on sterility, viability, and efficiency with advanced containers and packaging.
-
Accelerating A Global, FIH ADC Therapy Trial For Lung Cancer
Choose a development partner who can navigate global execution, ADC-specific challenges, and Project Optimus requirements so your first-in-human study is designed and positioned for success.
-
Application Of A Dual Spiking Strategy In Viral Clearance Studies
Explore how an alternative spiking strategy can streamline viral clearance studies, reduce material demands, and maintain compliance while addressing the challenges posed by MLV and MMV.
NEWSLETTER ARCHIVE
- 06.18.26 -- Scale Vaccine Production With Proven Cell Culture Solutions
- 06.18.26 -- Inside AstraZeneca's Fully Electrified Cell Therapy Facility
- 06.17.26 -- What's Slowing Your Cell & Gene Therapy Program?
- 06.17.26 -- Why Regulatory And Manufacturing Strategy Must Start Together
- 06.16.26 -- Reduce mAb Aggregates: Practical Strategies
- In Vivo Gene Editing Is Moving From Promise To Proof
- Driving Gene Therapy Beyond Rare Disease Will Define The Next Era Of CGT
- CGT Manufacturing Shifts From Capacity To Strategy
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
- Regeneron Advances In Vivo Gene Therapy For Hearing Loss
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections